New insider activity at Irhythm Technologies ( (IRTC) ) has taken place on February 26, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Irhythm Technologies has seen a wave of insider stock sales across its executive ranks. President & CEO Quentin Blackford led the activity by selling 25,540 shares for $3,458,371. Chief Business Officer and Chief Legal Officer Patrick Michael Murphy sold 7,805 shares valued at $1,056,875, while EVP & Chief Revenue Officer Sumi Shrishrimal disposed of 6,217 shares for $841,843. Chief Financial Officer Daniel G. Wilson sold 5,188 shares worth $702,507. Chief Commercial & Product Officer Chad Patterson offloaded 8,967 shares for $1,214,221, and Chief Medical/Scientific Officer and EVP Advanced Technology Minang Turakhia sold 7,804 shares totaling $1,056,739. In addition, Chief Accounting Officer Marc W. Rosenbaum sold 4,797 shares for $649,561, and EVP of Strategic Business Operations Mervin Smith sold 4,041 shares valued at $547,191. Together, these transactions represent significant insider selling across nearly all top leadership roles at Irhythm Technologies.
Recent Updates on IRTC stock
iRhythm shares fell about 6% as investors reacted to disclosure of a Department of Justice civil investigative demand tied to Zio AT reimbursement claims, which added regulatory overhang to the story. Despite strong Q4 results, analysts trimmed price targets mainly due to broader multiple compression among peers and lingering uncertainty around DOJ scrutiny, reimbursement dynamics, and timing of higher‑margin MCT growth.
The latest earnings call emphasized robust, volume‑driven revenue growth, first‑time quarterly profitability, and expanding margins, all supporting the long‑term growth case. However, guidance for slower growth, ongoing elevated operating and remediation expenses, and FDA‑related delays for the next‑gen MCT platform led analysts to modestly de‑risk their outlooks even while acknowledging solid execution in Zio AT and innovative channels.
Spark’s Take on IRTC Stock
According to Spark, TipRanks’ AI Analyst, IRTC is a Neutral.
The score is driven primarily by improving fundamentals and a positive outlook from the latest earnings call (growth, margin expansion, and rising free cash flow). Offsetting this are elevated balance-sheet leverage, still-negative profitability/negative P/E, and weak technicals with the stock trading below key moving averages.
To see Spark’s full report on IRTC stock, click here.
More about Irhythm Technologies
YTD Price Performance: -23.41%
Average Trading Volume: 604,759
Technical Sentiment Signal: Hold
Current Market Cap: $4.43B